RheADC SRL
RheADC reported total assets of 31,395 € at the end of the 2025 financial year (annual accounts filed with the NBB on 11 Jun 2026).
The score of RheADC shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
RheADC's annual accounts
| 2025 | |
|---|---|
| Net result | −124,379 € |
| Equity | −114,379 € |
| Cash | 11,388 € |
| EBITDA | −116,226 € |
| Total assets | 31,395 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 11 Jun 2026
RheADC's financial analysis
- Solvency-364.3%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of RheADC
RheADC's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1014.500.036
- VAT number
- BE1014500036
- Peppol
- Registered · 0208:1014500036 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 02 Oct 2024
- Registered office
- 3001 Leuven
- Latest accounts
- 2025 · filed on 11 Jun 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
RheADC (SRL) has been based in Leuven since 2024, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 124,379 € and equity of −114,379 €; its revenue is not published. Its solvency stands at -364.3%, below the median of its sector (56.0%).
Companies similar to RheADC
Companies in the same business, of comparable size and area, outside its group.
- Grand Medical (Europe) Research and experimental development on natural sciences and engineering Niel · balance sheet 135,260 €
- Inchinn Therapeutics Manufacture of basic pharmaceutical products Charleroi · balance sheet 51,394 €
- OncoRNA Research and experimental development on natural sciences and engineering Charleroi · balance sheet 20,034 €
- P & X Medical Research and experimental development on natural sciences and engineering Wevelgem · balance sheet 50,706 €
- Mentana DX Research and experimental development on natural sciences and engineering Evergem · balance sheet 229,998 €
- 4K Services Belgium Research and experimental development on natural sciences and engineering Etterbeek · balance sheet 59,971 €
- Gios Biostructures Research and experimental development on natural sciences and engineering Pelt · balance sheet 10,778 €
- Raya Therapeutic Manufacture of basic pharmaceutical products Leuven · balance sheet 5,330 €
Frequently asked questions about RheADC
What is the revenue of RheADC?
RheADC files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of RheADC?
In Belgium, the VAT number is the company number prefixed with BE: BE1014500036 for RheADC, if the company is VAT-registered. Its company number (CBE) is 1014.500.036.
Where is the registered office of RheADC?
According to the CBE register, the registered office of RheADC is in 3001 Leuven.
What is the equity of RheADC?
At the close of the 2025 financial year, the equity of RheADC amounts to -114,379 €, a solvency of -364.3% of total assets.
Who manages RheADC?
The register lists 2 active mandates at RheADC. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of RheADC
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →